Particulate Form (e.g., Powders, Granules, Beads, Microcapsules, And Pellets) Patents (Class 424/489)
  • Patent number: 10695440
    Abstract: Biomaterials suitable for use as drug eluting, Magnetic Resonance Imaging (“MRI”) detectable implants for vascular occlusion are provided, as are methods of producing such biomaterials. Further, methods of treating an individual suffering from a solid tumor are provided.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: June 30, 2020
    Assignee: Biosphere Medical, Inc.
    Inventors: Philippe Reb, Celine Chaix, Meriadeg Thomas
  • Patent number: 10695321
    Abstract: The invention relates to a novel use of the antimuscarinic agent glycopyrrolate, for example the salt glycopyrronium bromide. In particular, the invention relates to glycopyrrolate for use as a heart rate lowering agent and more particularly, but not exclusively, for use in patients suffering from respiratory conditions such as chronic obstructive pulmonary disease.
    Type: Grant
    Filed: January 31, 2016
    Date of Patent: June 30, 2020
    Assignee: HEPTARES THERAPEUTICS LIMITED
    Inventors: Susan Snape, Robert Tansley
  • Patent number: 10695288
    Abstract: A reactive oxygen species savaging emulsion; the emulsion comprising an injectable pharmaceutically acceptable composition and a polymeric poly(propylene sulfide) microsphere for targeted delivery to a site with elevated reactive oxygen species. In embodiments of the present invention, the microsphere is loaded with a biologically active agent.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: June 30, 2020
    Assignee: Vanderbilt University
    Inventors: Craig L. Duvall, John R. Martin, Kristin P. O'Grady, Christopher E. Nelson
  • Patent number: 10688054
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: June 23, 2020
    Assignee: INSPIRION DELIVERY SCIENCES LLC
    Inventors: Manish S. Shah, Ray Difalco
  • Patent number: 10687535
    Abstract: Described is a homogeneous gel composition with at least antimicrobial, antibacterial, and/or anti-viral properties comprising; a combination of a stable and homogeneous aqueous and/or polyol solution based chelated metal oxide liquid complex suspension and a gel composition free of chelated metal oxides comprising water, polyquaternium, glycerine and hyaluronic acid, wherein the homogeneous gel composition contains chelated metal oxide particles homogeneously suspended in the homogeneous gel composition such that a concentration of the chelated metal oxide particles contained within the homogeneous gel are in a concentration of at least 0.001 weight percent.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: June 23, 2020
    Assignee: AG Tech LLC
    Inventor: William Wingfield
  • Patent number: 10682412
    Abstract: The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: June 16, 2020
    Assignee: POLYPID LTD.
    Inventor: Noam Emanuel
  • Patent number: 10683365
    Abstract: Devices, compositions, and methods are described which provide a tubular nanostructure or a composite tubular nanostructure targeted to a lipid bilayer membrane. The tubular nanostructure includes a hydrophobic surface region flanked by two hydrophilic surface regions. The tubular nanostructure is configured to interact with a lipid bilayer membrane and form a pore in the lipid bilayer membrane. The tubular nanostructure may be targeted by including at least one ligand configured to bind to one or more cognates on the lipid bilayer membrane of a target cell.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: June 16, 2020
    Assignee: DEEP SCIENCE, LLC
    Inventors: Mahalaxmi Gita Bangera, Ed Harlow, Roderick A. Hyde, Muriel Y. Ishikawa, Edward K. Y. Jung, Eric C. Leuthardt, Nathan P. Myhrvold, Dennis J. Rivet, Elizabeth A. Sweeney, Clarence T. Tegreene, Lowell L. Wood, Jr., Victoria Y. H. Wood
  • Patent number: 10669305
    Abstract: The present invention relates to C-3 novel triterpenone with C-28 urea derivatives of formula (I); or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, tautomers, stereoisomers, prodrugs, compositions or combination thereof, wherein R1, R2, R3, W, J and X are as defined herein. The present invention also relates to pharmaceutical compositions comprising compounds of formula (I) useful for the treatment of viral diseases and particularly HIV mediated diseases.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: June 2, 2020
    Assignee: HETERO LABS LIMITED
    Inventors: Parthasaradhi Reddy Bandi, Rathnakar Reddy Kura, David Krupadanam Gazula Levi, Panduranga Reddy Adulla, Bhaskar Reddy Kasireddy, Carl Thomas Wild, David Eugene Martin, Theodore John Nitz
  • Patent number: 10668185
    Abstract: Disclosed herein are methods of manufacturing injectable microgel scaffolds, including methods of producing, purifying and concentrating microgel particles therein. The microgel scaffolds of the present disclosure are useful for a wide range of applications, such as stabilizing an implanted medical device in an implant site in a subject. The microgel scaffolds are fluidic during application and annealed or crosslinked after application to the implant site in the subject. The microgel scaffolds may contain various therapeutic agents, including antibiotics and analgesics, throughout the gel.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: June 2, 2020
    Assignee: TEMPO THERAPEUTICS, INC.
    Inventors: Westbrook Weaver, Stephanie Deshayes, Samuel Timko
  • Patent number: 10667749
    Abstract: A physical area network described herein enables significantly improved health monitoring and treatment by utilizing internal (in-body) mechanisms and information and external mechanisms and information.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: June 2, 2020
    Inventor: Lucas J. Myslinski
  • Patent number: 10660565
    Abstract: A physical area network described herein enables significantly improved health monitoring and treatment by utilizing internal (in-body) mechanisms and information and external mechanisms and information.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: May 26, 2020
    Inventor: Lucas J. Myslinski
  • Patent number: 10660828
    Abstract: Core-shell particles and methods of making and using thereof are described herein. The core is formed of or contains one or more hydrophobic materials or more hydrophobic materials. The shell is formed of or contains hyperbranched polyglycerol (HPG). The HPG coating can be modified to adjust the properties of the particles. Unmodified HPG coatings impart stealth properties to the particles which resist non-specific protein absorption and increase circulation in the blood. The hydroxyl groups on the HPG coating can be chemically modified to form functional groups that react with functional groups and adhere the particles to tissue, cells, or extracellular materials, such as proteins.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: May 26, 2020
    Assignee: Yale University
    Inventors: Yang Deng, Asiri Ediriwickrema, William M. Saltzman
  • Patent number: 10660848
    Abstract: The present invention relates to a sterile ophthalmic composition comprising castor oil and a medium chain triglyceride, to its use in medicine, in particular for the treatment and/or prevention of an ocular disease selected from the group consisting of dry eye, conjunctivitis, dermatitis, blepharitis, entropion, floppy eyelid syndrome, thyroid ophthalmopathy, pterygium, conjunctivochalasis, epithelial damage induced by preservatives, epithelial or anterior chamber damage induced by ocular surgery, limbal cell deficiency, corneal ulcers induced by physical or chemical agents, keratitis, episcleritis and uveitis.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: May 26, 2020
    Assignee: LABORATORIOS SALVAT, S.A.
    Inventors: Francisca Izquierdo Torres, Sandra Marchan Sancho, Isabel Delgado Gañán
  • Patent number: 10660861
    Abstract: Currently available glutaminase inhibitors are generally poorly soluble, metabolically unstable, and/or require high doses, which together reduce their efficacy and therapeutic index. These can be formulated into nanoparticles and delivered safely and effectively for treatment of pancreatic cancer and other glutamine addicted cancers. Studies demonstrate that nanoparticle delivery of BPTES, relative to use of BPTES alone, can be safely administered and provides dramatically improved tumor drug exposure, resulting in greater efficacy. GLS inhibitors can be administered in higher concentrations with sub-100 nm nanoparticles, since the nanoparticles package the drug into “soluble” colloidal nanoparticles, and the nanoparticles deliver higher drug exposure selectively to the tumors due to the enhanced permeability and retention (EPR) effect. These factors result in sustained drug levels above the IC50 within the tumors for days, providing significantly enhanced efficacy compared to unencapsulated drug.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: May 26, 2020
    Assignee: The Johns Hopkins University
    Inventors: Justin Hanes, Barbara S. Slusher, Anne Le, Jie Fu, Qingguo Xu
  • Patent number: 10660965
    Abstract: The present invention in one aspect provides methods of enhancing uptake of a therapeutic agent in a target tissue as well as methods of treating a disease (such as cancer) or enhancing effectiveness of treatment with a therapeutic agent in an individual by co-administering a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane with the therapeutic agent. The present invention in another aspect provides a method of treatment or a method of selecting patients for treatment of a disease (such as cancer) with the combination of a therapeutic agent and a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane based on one or more characteristics of the target tissue that correlates or indicates the capability of getting enhanced therapeutic agent uptake as a result of the co-administration of the taxane nanoparticle composition in the target tissue (referred to as “the drug uptake capability”).
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: May 26, 2020
    Assignee: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong
  • Patent number: 10660975
    Abstract: Disclosed is a composition including magnetic nanoparticles for use in the treatment of a tissue volume including pathological cells in an individual, wherein a portion only of the tissue volume is occupied by the magnetic nanoparticles upon administration of the composition to the individual and the magnetic nanoparticles are excited by radiations.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: May 26, 2020
    Assignee: NANOBACTERIE
    Inventor: Edouard Alphandery
  • Patent number: 10653633
    Abstract: A composition includes particles of pimobendan with an integral coating of a carrier matrix which serve to ensure a rapid dissolution of the active substance at each pH condition representing the gastrointestinal tract and therefore a reliable absorption, and a method of pimobendan microencapsulation using the spray congealing technology and incorporating the coated particles into oral formulations, for example into tablets.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: May 19, 2020
    Inventor: Péter Laczay
  • Patent number: 10653690
    Abstract: There is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist. The pharmaceutical composition includes a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The pharmaceutical composition is preferably in the form of a powder produced by spray-drying, which is subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. The pharmaceutical composition may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: May 19, 2020
    Assignee: OREXO AB
    Inventors: Jonas Sävmarker, Robert Rönn, Andreas Fischer
  • Patent number: 10646451
    Abstract: Embodiments disclosed herein relates to ganglioside GM3-containing mixed lipids nanoparticles having an overall size between 60-100 nm, the making thereof and the uses. The nanoparticles selectively targeted to CD169+ expressing cells such as dendritic cells and macrophage. The nanoparticles are endocytosed by the CD169+ expressing cells.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: May 12, 2020
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Bjoern Markus Reinhard, Suryaram Gummuluru
  • Patent number: 10632081
    Abstract: Disclosed is an intralymphatic delivery method for treating lymphatic cancer using hyaluronan nanoparticles. These nanoparticles include a hyaluronic acid derivative and a platinum compound. The hyaluronan derivative includes hyaluronic acid, modified histidine and optionally one or more of a polymer or a C4-C20 alkyl. The hyaluronic acid derivative may include linking group(s) that connect the polymer or the C4-C20 alkyl to the hyaluronic acid. The platinum compound includes dichloro(1,2-diaminocyclohexane) platinum (DACHPt), cisplatin and oxaliplatin. This intralymphatic delivery method offers significant advantages for the use of platinum medicines in treating lymphatic cancer.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: April 28, 2020
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Chih-Peng Liu, Ya-Chin Lo, Ming-Cheng Wei, Maggie Lu, Shuen-Hsiang Chou, Shih-Ta Chen, Hsiang-Wen Tseng
  • Patent number: 10624889
    Abstract: An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: April 21, 2020
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuya Sato, Takuya Minowa, Yusuke Hoshika, Hidekazu Toyofuku
  • Patent number: 10624854
    Abstract: A method for preparing a degradable drug-loaded microsphere for embolization and a product obtained therefrom, includes the steps of: dissolving a degradable material in an organic solvent, then adding a drug and mixing well to form a suspension or solution; then pouring the drug-containing suspension or solution into an aqueous solution of polyvinyl alcohol, stirring, and thereafter adding water twice for dilution, to prepare the degradable drug-loaded microsphere. The microsphere prepared by the present invention has the advantages of having a controllable particle size, a high drug loading capacity, and a regular spherical shape, being convenient for sieve sizing and accurate particle-size indication, and being accurately targeted to an embolized blood vessel, and the like, and thus has a good application prospect in interventional embolization therapy.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: April 21, 2020
    Assignee: Shandong Rientech Medical Technology Co., Ltd
    Inventors: Haijun Zhang, Shoutao Lu, Hairong Xu, Liming Liu, Wenrui Cao, Maoquan Li, Chao Zhou, Yuxia Yin, Cuihai Duan, Wenbo Hou, Guang Liu
  • Patent number: 10617644
    Abstract: A composition for use in the treatment of fistula, the composition comprising activated carbon.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: April 14, 2020
    Assignee: FERRING B.V.
    Inventors: Soren Halskov, Mats Ekelund
  • Patent number: 10603287
    Abstract: The present invention relates to a product, method of making and method of using an albumin sphere suspension for controlling bleeding of a non-thrombocytopenic patient before, during and after surgery. An albumin sphere suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of controlling bleeding in vivo. The suspension is prepared by mixing at near freezing temperatures an albumin solution, a sub-stabilizing concentration of glutaraldehyde solution and an alcohol solution containing a stabilizing concentration of glutaraldehyde. The mixed suspension is warmed, and glycine and sorbitol being added. Lyophilization of the suspension can be performed for stabilization of the suspension.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: March 31, 2020
    Assignee: PTLNV, LLC, Series Three (3)
    Inventor: Richard C. K. Yen
  • Patent number: 10596178
    Abstract: The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,-2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: March 24, 2020
    Assignee: Novartis AG
    Inventors: Elisabete Goncalves, Christin Tauchmann, Shau-Fong Yen, Sudha Vippagunta, Zhixin Zong
  • Patent number: 10596118
    Abstract: An ospemifene solid dispersion for enhancing solubility and bioavailability, and methods of preparation thereof are disclosed. The solid dispersion comprises an active pharmaceutical ingredient, such as ospemifene, and a hydfophilie carrier, such as copovidone, hypromellose acetate succinate, polyvinylpyrrolidine, a polyvinylpyrrolidine/vinyl acetate co-polymer, hydroxyl propyl methylcellulose, hypromellose acetate succinate, a Eudragit® compound, hydroxypropylcellulose, a polyvinyl caprolactam-polyvinyl acetate polyethylene glycol graft co-polymer, hydroxypropyl methylcellulose phthalate, and mixtures thereof, and optionally a surfactant The ospemifene solid, dispersions can be used in methods of treating a symptom related, to menopause, such as vaginal dryness or sexual dysfunction, or in methods of treating osteoporosis.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: March 24, 2020
    Assignee: Shionogi, Inc.
    Inventors: Zhengming Chen, Xiaoming Chen, Kevin Halloran
  • Patent number: 10583082
    Abstract: The present invention relates to inhalation formulations of drugs in the form of dry powder for inhalation administration deliverable as such with an inhaler and provided with high deliverability, respirability and stability. In particular, the invention relates to a pharmaceutical composition for inhalation in the form of powder comprising at least a first and a second powder, in which at least said first powder contains an active agent in an amount greater than 1% by weight with respect to the weight of said first powder. Both the powders comprise leucine in an amount ranging from 5 to 70% by weight with respect to the weight of each powder and a sugar in an amount ranging from 20 to 90% by weight with respect to the weight of each powder. The composition has a fine particle fraction (FPF) greater than 60% and a delivered fraction (DF) greater than 80.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: March 10, 2020
    Assignee: ZAMBON S.P.A.
    Inventors: Giovanni Caponetti, Loretta Maggi, Cristina Veneziani, Paolo Ventura, Laura Zanellotti
  • Patent number: 10576025
    Abstract: The present invention relates to a composition comprising particles of at least one polymer that is surface-stabilized with a stabilizer, the polymer of the particles being a C1-C4 alkyl (meth)acrylate polymer; the stabilizer being an isobornyl (meth)acrylate polymer chosen from isobornyl (meth)acrylate homopolymer and statistical copolymers of isobornyl (meth)acrylate and of C1-C4 alkyl (meth)acrylate present in an isobornyl (meth)acrylate/C1-C4 alkyl (meth)acrylate weight ratio of greater than 4, at least one hydrocarbon-based oil and at least one amorphous hydrocarbon-based block copolymer obtained by polymerization of at least one monomer of unsaturated hydrocarbon type comprising 2 to 5 carbon atoms and containing one or two ethylenic unsaturations. The invention also relates to a process for making up and/or caring for keratin materials, in which said composition is applied.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: March 3, 2020
    Assignee: L'OREAL
    Inventors: Laure Daubersies, Christel Lison, Stephane Douezan, Hy Si Bui, Rita El-Khouri
  • Patent number: 10578598
    Abstract: Nanoreactors comprising a metal precursor in a carrier are provided as well as methods of initiating, methods of preparing, and methods of using nanoreactors. In some embodiments, upon exposure to heat, the metal precursor forms nanoparticles that can be detected, e.g., by detecting a color change in the nanoreactor and/or by detecting the number and/or size and/or size distribution and/or shape of the nanoparticles. The nanoreactors can be used, in some embodiments, as time-temperature indicators for perishable goods.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: March 3, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Sundaram Gunasekaran, Yi-Cheng Wang
  • Patent number: 10570295
    Abstract: A coating is described herein, including a material chosen from the group consisting of rubber, ceramic, metal, concrete, epoxy, polyurethane, and polyurea, a first carbon nanotube (FCN) filled with a first healing agent, wherein the first carbon nanotube has first and second ends, wherein a first FCN end cap is closed on the first end of the FCN and a second FCN end cap is closed on the second end of the FCN, and a second carbon nanotube (SCN) filled with a second healing agent, wherein the second carbon nanotube has first and second ends, wherein a first SCN end cap is closed on the first end of the SCN and a second SCN end cap is closed on the second end of the SCN, wherein the first and second carbon nanotubes are mixed in the material, wherein the end caps are removable by a hydrolysis reaction.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: February 25, 2020
    Assignee: Tesla Nanocoatings, Inc.
    Inventor: Jorma Antero Virtanen
  • Patent number: 10570296
    Abstract: A self-healing polymer is described herein, including a first carbon nanotube filled with at least a first healing agent, wherein the first carbon nanotube has first and second ends, wherein a first end cap is closed on the first end of the first carbon nanotube and a second end cap is closed on the second end of the first carbon nanotube, and a second carbon nanotube filled with at least a second healing agent, wherein the second carbon nanotube has first and second ends, wherein a first end cap is closed on the first end of the second carbon nanotube and a second end cap is closed on the second end of the second carbon nanotube.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: February 25, 2020
    Assignee: Tesla Nanocoatings, Inc.
    Inventor: Jorma Antero Virtanen
  • Patent number: 10562983
    Abstract: Disclosed are a method for preparing hydroxypropyl methylcellulose acetate succinate (HPMCAS) grains and HPMCAS grains. The disclosed method for preparing HPMCAS grains comprises: a step of esterifying hydroxypropyl methylcellulose (HPMC), acetic anhydride, and succinic anhydride in a reaction medium in the presence of a catalyst so as to obtain a reaction solution containing HPMCAS (esterification step); and a step of continuously or intermittently putting the reaction solution into water so as to form grains (granulating step).
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: February 18, 2020
    Assignee: LOTTE FINE CHEMICAL CO., LTD.
    Inventors: Sung Hwan Bang, Ju Hee Shin, Jin Ryul Son, Kyung Yeol Park, Jeong Hee Chun, Ji Seon Jeong, Sang Youb Lee
  • Patent number: 10562947
    Abstract: The described invention provides compositions and methods for treating asthma, a disease, condition or pathologic process whose progression is characterized by one or more of aberrant fibroblast proliferation and extracellular matrix deposition producing constriction in an airway, airway remodeling, and airway obstruction in lung tissue. The method includes administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein the therapeutic amount of the polypeptide is effective to reduce the constriction of small airway dimensions and airway obstruction, treat airway remodeling, or a combination thereof.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: February 18, 2020
    Assignee: MOERAE MATRIX, INC.
    Inventors: Cynthia Lander, Colleen Brophy
  • Patent number: 10561745
    Abstract: Materials and methods for synthesizing magnetic core/gold shell nanoparticles and magneto-plasmonic nanostars are provided. Formulations comprising nanoparticles optionally bound to or co-loaded with a therapeutic agent encapsulated within liposomes are provided. A method for treating diseases (e.g., brain diseases) in a subject by administering to the subject a formulation comprising the nanoparticle formulation is also provided. Further, a method is provided for imaging a target site of a subject following the administering of the nanoparticle formulations.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: February 18, 2020
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Asahi Tomitaka, Madhavan Nair
  • Patent number: 10561622
    Abstract: The present invention is directed to a process for the preparation of enteric microparticles comprising nanoparticles, wherein the nanoparticles comprise a matrix and an active ingredient. The microparticles obtained by such process are usable various multiparticulate pharmaceutical formulations such as extemporaneous dosage forms (powder for reconstitution).
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: February 18, 2020
    Assignee: Merck Patent GmbH
    Inventors: Andrea Hanefeld, Markus Weigandt, Stefan Schiller, Marc Schneider, Michael C. Lehr
  • Patent number: 10557081
    Abstract: The present invention relates to light-converting materials which comprise semiconductor nanoparticles and an unactivated crystalline material, where the semiconductor nanoparticles are located on the surface of the unactivated crystalline material. The present invention furthermore relates to the use of the light-converting material in a light source. The present invention furthermore relates to a light-converting mixture, to a light source, to a lighting unit which contains the light-converting material according to the invention, and to a process for the production of the light source.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: February 11, 2020
    Assignee: Merck Patent GmbH
    Inventors: Norbert Stenzel, Andrea Opolka, Bernhard Rieger, Stefan Tews
  • Patent number: 10555911
    Abstract: Brain-penetrating polymeric nanoparticles that can be loaded with drugs and are optimized for intracranial convection-enhanced delivery (CED) have been developed. In the preferred embodiment, these are loaded with FDA-approved compounds, identified through library screening to target brain cancer stem cells (BSCSs). The particles are formed by emulsifying a polymer-drug solution, then removing solvent and centrifuging at a first force to remove the larger particles, then collecting the smaller particles using a second higher force to sediment the smaller particles having a diameter of less than 100 nm, more preferably less than 90 nanometers average diameter, able to penetrate brain interstitial spaces.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: February 11, 2020
    Assignee: Yale University
    Inventors: Jiangbing Zhou, Toral R. Patel, Joseph M. Piepmeier, William Mark Saltzman
  • Patent number: 10548860
    Abstract: Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. suspended in a carrier compatible with the tissue of interest, is topically applied to the surface of tissues at the site of anastomosis. The nanoparticles are comprised of the active agent and a pharmaceutically acceptable stabilizer.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: February 4, 2020
    Assignees: The Board Of Trustees of The Leland Stanford Junior University, The United States Government as Represented By The Department Of Veterans Affairs, The Johns Hopkins University
    Inventors: Mark R. Nicolls, Jayakumar Rajadas, Geoffrey C. Gurtner, Xinguo Jiang, Gundeep Dhillon, Gregg L. Semenza
  • Patent number: 10543295
    Abstract: Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: January 28, 2020
    Assignee: MicroVention, Inc.
    Inventors: Gregory M. Cruise, Steve Plotkin, Xinping Wu
  • Patent number: 10543177
    Abstract: Provided herein are compositions and related methods for the treatment of herpes simplex virus (HSV) induced blisters and resulting ulcerative lesions. The composition includes at least one antiviral agent that is a long-chain aliphatic compound, and at least one topical corticosteroid.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: January 28, 2020
    Inventor: Kevin Mrohs
  • Patent number: 10526284
    Abstract: What is described is a compound of formula I consisting of a compound in which R1 is a branched chain alkyl consisting of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons; L1 and L2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X1 is S or O; R3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 7, 2020
    Assignee: ARCTURUS THERAPEUTICS, INC.
    Inventors: Joseph E. Payne, Padmanabh Chivukula, Priya Karmali, Steven P. Tanis
  • Patent number: 10517828
    Abstract: The present invention relates to inhalation formulations of drugs in the form of dry powder for inhalation administration deliverable as such with an inhaler and provided with high deliverability, respirability and stability. In particular, the invention relates to a pharmaceutical composition for inhalation use in powder form comprising a first powder comprising at least a powder (a1) comprising an active agent or a pharmaceutically acceptable salt thereof, in an amount greater than 1% by weight of the powder, leucine in an amount from 5 to 70% by weight of said powder, a sugar in an amount from 20 to 90% by weight of the powder; and a second powder comprising a mixture of a first lactose which has an X50 from 35 to 75 ?m, with a second lactose which has an X50 from 1.5 to 10 ?m, the content of the first and second lactose in the mixture are respectively from 85% to 96% and from 4% to 15%.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: December 31, 2019
    Assignee: ZAMBON S.P.A.
    Inventors: Loretta Maggi, Giovanni Caponetti, Heike Butti, Cristina Veneziani, Laura Zanellotti
  • Patent number: 10514381
    Abstract: Lyophilized chromophoric polymer dot compositions are provided. Also disclosed are methods of making and using the lyophilized compositions, methods of dispersing the lyophilized compositions in aqueous solutions and kits supplying the compositions.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 24, 2019
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Daniel T. Chiu, Wei Sun, Jiangbo Yu, Changfeng Wu, Fangmao Ye
  • Patent number: 10512672
    Abstract: This invention provides compositions and methods for preventing inflammatory diseases of the joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of the ligament, synovitis, gout, and systemic lupus erythematosus, wherein the methods include injecting into the inflamed joint a therapeutic anti-inflammatory composition comprising a bacterial or viral IL-10 expression construct, wherein the IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: December 24, 2019
    Assignees: Xalud Therapeutics, Inc., The Regents of the University of Colorado, a Body Corporate
    Inventors: Raymond A. Chavez, Linda R. Watkins, Robert Landry
  • Patent number: 10493105
    Abstract: A cell for treating neurodegenerative disease treated with angelica extract is provided. The pharmaceutical composition comprises the cell for treating neurodegenerative disease and can significantly increase and recover the number of dopaminergic neurons to achieve the goal for treating neurodegenerative disease.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: December 3, 2019
    Assignee: TAIWAN MITOCHONDRION APPLIED TECHNOLOGY CO., LTD
    Inventors: Shinn-Zong Lin, Horng-Jyh Harn, Shih-Ping Liu, Han-Chung Cheng, Chi-Tang Tu
  • Patent number: 10493161
    Abstract: There are provided a solution for spray drying having a high transmittance and markedly reduced generation of undissolved matter; and a method for producing a solid dispersion by using the solution for spray drying so that clogging with the undissolved matter is reduced and dissolution is improved. More specifically, there is provided a solution for spray drying comprising hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more, a solvent, and a drug. There is also provided a method for producing a solid dispersion comprising the step of removing the solvent from the spray drying solution.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: December 3, 2019
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Shogo Warashina, Fumie Kusaki, Kazuki Kikuchi, Sakae Obara, Naosuke Maruyama
  • Patent number: 10487181
    Abstract: The invention provides a metallopolymer coordination network comprising one or more coinage or similar metals and a glyme or glyme-equivalent. The composition has an amorphous polymer network that is significantly stronger than previously reported supramolecular hydrogels synthesized without glyme. Glyme chain length and water content strongly influence the mechanical, electronic, and optical behavior of the network.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: November 26, 2019
    Assignee: Colorado State University Research Foundation
    Inventors: William Scott Compel, Christopher J. Ackerson, O. Andrea Wong
  • Patent number: 10485761
    Abstract: In one aspect, the present invention provides sterile microparticle compositions comprising biodegradable microparticles, which comprise at least one biodegradable polymer. In other aspects, the present invention provides methods of making and using such compositions as well as articles of manufacture and kits containing the same.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: November 26, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventors: Derek O'Hagan, Manmohan Singh, Siddhartha Jain, Padma Malyala
  • Patent number: 10485856
    Abstract: Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and/or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T cells and may be used to activate T cells ex vivo or in vivo for adoptive or active immunotherapy.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: November 26, 2019
    Assignee: Yale University
    Inventors: Tarek M. Fahmy, Lisa D. Pfefferle, Gary L. Haller, Tarek R. Fadel
  • Patent number: 10485787
    Abstract: In the present invention there is provided a pharmaceutical composition for oral administration which comprises bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient and which shows a dissolution of the bendamustine of at least 60% in 20 minutes, 70% in 40 minutes and 80% in 60 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5. The invention further relates to the above pharmaceutical composition for use for the oral treatment of a medical condition which is selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia, acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer and non-small cell lung cancer.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: November 26, 2019
    Assignee: Astellas Deutschland GmbH
    Inventors: Ulrich Patzak, Taoufik Ouatas